Diagnostic Criteria for Temporomandibular Disorders Clinical ExaminationBlood test
Diagnostic Criteria for Temporomandibular Disorders Clinical Examination: Clinical examination made by experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the DC/TMD.
Blood test: Blood samples will be tested to investigate two polymorphisms of genes encoding proteins for serotonin receptors HTR2A - rs4941573 in intron 3 and dopamine DRD3 - rs6280 (Ser9Gly) and levels of serotonin, dopamine, Gamma-aminobutyric acid (GABA), Tumor Necrosis Factor α (TNF-α), CGRP, SERT, interleukin 1B, interleukin 6, interleukin 8, interleukin 10 and interleukin 17A.
Study summary
The aim of this study is to investigate the relationship of psychological aspects, selected blood parameters, pain, central sensitization, and muscle electromyography activity in patients with chronic masticatory muscle pain.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria for study group:
* Masticatory muscle pain for at least 3 months, based on DC/TMD, at least 18 y.o
Exclusion Criteria:
* severe neurological or psychiatric diseases, use of drugs that may affect the neuromuscular system, alcohol or drug addiction, cancer or pregnancy, previous head surgery
Inclusion criteria for control group:
* no pain in masticatory muscles, age of at least 18 y.o Exclusion criteria the same as for study group
Primary outcome measure(s)
Relationship between masticatory muscle pain and polimorphism of serotonin receptor gene HTR2A - rs4941573 and dopamine receptor gene DRD3 - rs6280 — January 3, 2023 - January 3, 2024 Each participant will undergo genetical blood test.
Relationship between masticatory muscle pain and serotonin and dopamine levels. — January 3, 2023 - January 3, 2024 Each participant will undergo blood test.
Relationship between masticatory muscle pain and Gamma-aminobutyric acid (GABA), Tumor Necrosis Factor α (TNF-α), CGRP, SERT, interleukin 1B, interleukin 6, interleukin 8, interleukin 10 and interleukin 17A. — January 3, 2023 - January 3, 2024 Each participant will undergo blood test.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
